ClinicalTrials.gg
CompletedNCT03235570Updated May 29, 2020

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

A Phase 1 interventional study of Pemigatinib in Solid Tumors, sponsored by Incyte Corporation. Completed at 12 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-05-29.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2020, 6 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability of pemigatinib in Japanese subjects with advanced malignancies.

02

Conditions studied

  • Solid Tumors

Keywords

  • Solid tumor
  • malignancy
  • fibroblast growth factor receptor (FGFR)
  • fibroblast growth factor (FGF)/FGFR alteration
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 44 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First generation Japanese; subject was born in Japan and has not lived outside of Japan for a total of > 10 years and subject can trace maternal and paternal Japanese ancestry.
  • Part 1: Any confirmed advanced solid tumor . Subjects enrolled at a lower dose level expansion cohort are required to have documented FGF/FGFR alterations and baseline and on-treatment tumor for testing of biomarkers.
  • Part 2: Any histologically confirmed advanced solid tumor malignancy with a FGF/FGFR alteration
  • Advanced or and recurrent cancer where an appropriate treatment option is not available.
  • > 12 weeks.
  • (ECOG) performance status: Part 1: 0 or 1; Part 2: 0, 1, or 2.
  • Genomic testing is mandatory for all enrolled subjects. Archival tumor specimen of at least 7 slides or willingness to undergo a pretreatment tumor biopsy to provide a tumor block or at least 7 unstained slides. Archival tumor biopsies are acceptable at baseline and should be no more than 2 years old (preferably less than 1 year old and collected since the completion of the last treatment); subjects with samples older than 2 years old and/or with sequencing report from the central laboratory require approval from the sponsor medical monitor for exemption from tumor biopsy or tumor sample requirement.

Exclusion criteria

Exclusion Criteria:

  • Treatment with other study drug for any indication for any reason, or receipt of anticancer medications within 21 days or 5 half-lives (whichever is longer) before first dose of study drug (6 weeks for mitomycin-C or nitrosoureas, 7 days for tyrosine kinase inhibitors).
  • Prior receipt of a selective FGFR inhibitor.
  • Laboratory and medical history parameters outside Protocol-defined range.
  • History and/or current evidence of ectopic mineralization/calcification including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcification.
  • Current evidence of corneal disorder/keratopathy including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis, confirmed by ophthalmologic examination.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Pemigatinib

    Part 1 is an open-label dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.

    Drug: Pemigatinib

Interventions

  • Pemigatinib at the protocol-defined dose administered once daily.

    Also known as: INCB054828

06

What researchers measure

Primary outcomes

  1. Safety and tolerability assessed by monitoring frequency, duration, and severity of adverse events (AEs)

    An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a subject provides informed consent.

    Time frame: Baseline through 30 days after end of treatment, up to approximately 16 months.

Secondary outcomes

  1. Overall response rate in subjects with measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Defined as proportion of subjects who meet the response criteria (complete response + partial response) as appropriate for the tumor type.

    Time frame: Baseline and Day 15 of every third treatment cycle, up to approximately 6 months

  2. Pharmacodynamics of pemigatinib assessed by changes in serum phosphorus level

    Analyzed to look for differences that may be associated with response or safety as well as significant changes associated with treatment.

    Time frame: Baseline and protocol-defined timepoints throughout the treatment period, up to approximately 6 months

  3. Observed Plasma Concentration of pemigatinib

    PK parameters will be calculated from the blood plasma concentrations of pemigatinib using standard noncompartmental (model independent) PK methods.

    Time frame: During the first cycle, up to Day 16

07

Study locations

12 sites
  • Aichi Cancer Center Hospital
    Aichi, 464-8681, Japan
  • Chiba Cancer Center
    Chiba, 260-8717, Japan
  • National Cancer Central Hospital East
    Chiba, 277-8577, Japan
  • Kyusyu Cancer Center
    Fukuoka, 811-1395, Japan
  • Kanazawa University Hospital
    Ishikawa, 920-8641, Japan
  • Kanagawa Cancer Center
    Kanagawa, 241-8515, Japan
  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
  • Saitama Cancer Center
    Saitama, 362-0806, Japan
  • Hokkaido Cancer Center
    Sapporo, 003-0804, Japan
  • Shizuoka Cancer Center
    Shizuoka, 411-8777, Japan
  • National Cancer Central Hospital
    Tokyo, 104-0045, Japan
  • JFCR Ariake Hospital
    Tokyo, 135-8550, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Mar 2020, 31 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 31 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2017
First posted
Aug 1, 2017
StartActual
Aug 1, 2017
Primary completionActual
Mar 4, 2020
CompletionActual
Mar 4, 2020
Last update
May 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03235570
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 1, 2017
Start date
Aug 1, 2017
Primary completion
Mar 4, 2020
Completion
Mar 4, 2020
Last update
May 29, 2020

Study contacts

Ekaterine Asatiani, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion